Business Context and Reporting Period
This Form 8-K Current Report was filed by Assembly Biosciences, Inc. on September 26, 2014, with the earliest event reported on that date. The filing details a registered direct offering of common stock and the termination of a prior sales agreement.
Key Financial Metrics and Transaction Details
- Offering Size: 1,959,000 shares of common stock.
- Purchase Price: $8.04 per share.
- Placement Agent Fee: 5.0% of gross proceeds.
- Expected Closing Date: On or about October 6, 2014.
- Terminated Agreement Proceeds: The terminated "at the market" program with Cantor Fitzgerald & Co. had generated aggregate sales proceeds of $20,521,567 prior to termination.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transactional report rather than a periodic financial statement.
Material Changes
- Capital Raise: Entry into subscription agreements for a registered direct offering, representing a significant change in capital structure pending closing.
- Agreement Termination: Termination of the Sales Agreement with Cantor Fitzgerald & Co. effective September 26, 2014, with no termination penalties incurred.
- Lock-Up Period: The company, its directors, executive officers, and largest stockholder agreed to a 90-day lock-up period (starting October 1, 2014) prohibiting the sale or transfer of common stock without consent from the placement agent.
Outlook, Risks, and Management Commentary
The offering is subject to customary closing conditions. The filing notes that the purchase price represents a premium to the closing bid price on September 30, 2014. Management has engaged William Blair & Company, L.L.C., as the sole placement agent. The filing incorporates by reference a press release and legal opinion regarding the validity of the share issuance.
Investor Verification Checklist
- Verify the final closing of the offering on or about October 6, 2014.
- Confirm the total gross proceeds and net proceeds after the 5.0% placement agent fee.
- Review the attached Subscription Agreement (Exhibit 10.27) and Placement Agent Agreement (Exhibit 10.28) for specific covenants.
- Monitor the 90-day lock-up expiration date for potential share sales by insiders.
- Check subsequent filings for the impact of the new capital on the company's cash position and operational runway.